gRNA Market Size to Worth 2780.68 Million By 2033

Prathamesh

9 months ago

The global gRNA market size is expected to increase USD 2780.68 million by 2033 from USD 503.74 million in 2023 with a CAGR of 18.63% between 2024 and 2033.

Key Points

The North America gRNA market size accounted for USD 272.02 million in 2023 and is predicted to cross around USD 1,515.47 million by 2033, at a CAGR of 18.73% from 2024 to 2033.
North America dominated the market with the largest revenue share of 54% in 2023.
Asia Pacific is expected to host the fastest growing market during the forecast period of 2024-2033.
By product & service type, the products segment led the global market in 2023.
By product & service type, the custom gRNA synthesis services segment is expected to grow significantly in the market during the forecast period.
By gRNA type, the research-use segment dominated the market in 2023.
By gRNA type, the GMP-grade segment is expected to gain a significant share of the market during the forecast period.
By application type, the genome engineering segment dominated the market in 2023 and is expected to grow at the fastest rate during the forecast period.
By end-use type, the pharmaceutical & biotechnology companies segment has held a major revenue share of 50% in 2023.
By end-use type, the academic research institutes segment will grow at the fastest rate over the forecast period.

gRNA Market Size 2024 to 2033

The gRNA market is integral to the rapid advancements in genetic research and therapeutic applications. Guide RNAs are essential components in CRISPR systems, guiding the Cas9 enzyme to specific DNA sequences for precise editing. This technology enables targeted modifications of genes, offering potential breakthroughs in treating genetic disorders, developing new therapies, and enhancing agricultural biotechnology.

Get a Sample: https://www.precedenceresearch.com/sample/4536

Growth Factors

Several factors contribute to the growth of the gRNA market. The increasing adoption of CRISPR technology across biotechnology and pharmaceutical industries drives demand for gRNAs. Research and development activities focused on expanding CRISPR applications further fuel market growth. Additionally, government initiatives supporting genome editing research and the rising investment in biotechnology contribute significantly to market expansion.

Region Insights

The gRNA market exhibits a global presence, with North America and Europe leading in research and commercialization efforts. These regions benefit from advanced healthcare infrastructure, robust research funding, and a supportive regulatory environment for biotechnology innovations. Asia-Pacific is emerging as a key growth region, driven by investments in biotechnology research, increasing collaborations with global players, and rising healthcare expenditures.

gRNA Market Scope

Report Coverage	Details
Market Size by 2033	USD 2780.68 Million
Market Size in 2023	USD 503.74 Million
Market Size in 2024	USD 597.59 Million
Market Growth Rate from 2024 to 2033	CAGR of 18.63%
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	Product & Service Type, gRNA Type, Application, End-use and Regions
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

gRNA Market Dynamics

Drivers

Key drivers of the gRNA market include the versatility and specificity of CRISPR-Cas systems in genome editing, which offer unparalleled precision in modifying genetic material. The potential applications in treating genetic disorders, developing personalized medicine, and enhancing crop resilience against diseases and environmental stresses drive market adoption. Moreover, advancements in delivery technologies for CRISPR components and increasing partnerships among biotechnology firms and academic institutions propel market growth.

Opportunities

The gRNA market presents significant opportunities for innovation and commercialization. Ongoing research to improve CRISPR efficiency, reduce off-target effects, and expand the range of editable genetic sequences enhances market prospects. The growing demand for customized therapies, such as gene therapies and cell-based treatments, opens new avenues for gRNA applications. Furthermore, collaborations between biotech companies and healthcare providers to develop CRISPR-based diagnostics and therapeutics represent promising opportunities.

Challenges

Despite its potential, the gRNA market faces challenges such as ethical concerns regarding genome editing, particularly in human embryos. Regulatory complexities and varying approval processes across different regions pose barriers to market entry and commercialization. Additionally, addressing off-target effects and ensuring the safety and efficacy of CRISPR-based therapies remain critical challenges for researchers and developers in the field.

gRNA Market Companies

Synthego
Horizon Discovery Ltd
Synbio Technologies
Takara Bio Inc.
GENEWIZ (Azenta Life Sciences)
Merke KGaA
Jena Bioscience GmbH
System Biosciences, LLC
Agilent Technologies Inc.
Thermo Fischer Scientific Inc.
Revvity Inc. (Horizon Discovery Ltd)

Recent Developments

In October 2023, a leading provider of genome engineering solutions, Synthego, launched its transformative product, IND-enabling (INDe) gRNAs, which helps to bridge critical preclinical gaps to promote CRISPR-based gene and cell therapies. This innovation offers researchers a high-quality designed gRNA, especially for IND-enabling and GLP-regulated preclinical studies, including complete IND-compliant documentation and materials in their production and design.
In May 2024, in Dubai, a pioneer in genomic research & technology, BioAro officially launched a revolutionary software, “PanOmiQ,” the world’s fastest multi-genomic analysis solutions. It helps to reduce health risks.

Segments Covered in the Report

By Product & Service Type